v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net profit/(loss) $ 3,401 $ (65,954)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 8,156 6,647
Amortization 234 322
Gain on bargain purchase   (22,049)
Share-based compensation expense 9,215 8,692
Unrealized foreign exchange losses 3,164 709
Accretion on available-for-sale debt securities (544) (1,595)
Other (104) 253
Changes in operating assets and liabilities:    
Decrease/(increase) in receivables and other operating assets 5,426 (709)
Increase in inventories (1,869)  
Increase in non-current assets (926)  
Increase/(decrease) in payables and other current liabilities 1,173 (7,792)
Increase in borrowings and other non-current liabilities 1,480  
Decrease in deferred revenue (67,808) (44,728)
Net cash (used in) operating activities (39,002) (126,204)
Cash flows from investing activities    
Acquisition of property, plant and equipment (667) (3,854)
Acquisition of intangible assets (880) (199)
Cash from acquisition of TCR2 Therapeutics Inc.   45,264
Maturity or redemption of marketable securities   139,243
Investment in marketable securities (65,701) (73,026)
Other 129 913
Net cash (used in)/provided by investing activities (67,119) 108,341
Cash flows from financing activities    
Proceeds from issuance of borrowings, net of discount 49,500  
Proceeds from issuance of common stock from offerings, net of commissions and issuance costs 29,171 623
Proceeds from exercise of stock options 77 183
Net cash provided by financing activities 78,748 806
Effect of currency exchange rate changes on cash, cash equivalents and restricted cash (222) 527
Net (decrease) in cash, cash equivalents and restricted cash (27,595) (16,530)
Cash, cash equivalents and restricted cash at start of period 147,017 109,602
Cash, cash equivalents and restricted cash at end of period $ 119,422 $ 93,072

Source